摘要
目的：本实验为一前瞻性随机化对照研究，以高剂量表阿霉素－丝裂霉素－顺铂，常规剂量表阿霉素－丝裂霉素－顺铂作比较，初治非小细胞肺癌（ＮＳＣＬＣ），评价其疗效及毒副作用．方法：治疗ＮＳＣＬＣ共４０例．分高剂量组和常规剂量组（Ａ、Ｂ）各２０例．男性２５例，女性１５例．病理类型以腺癌为主（２６例）， Ⅲａ期４例，Ⅲｂ期１７例，Ⅳ期１９例．全部为初治病人．结果：高剂量组（Ａ）总有效率（６５％）高于常规剂量组（Ｂ）（４５％），中位缓解期Ａ组３．１个月，Ｂ组２．２个月；中位生存期Ａ组８．７个月，Ｂ组７．１个月．表阿霉素的剂量限制毒性为心脏毒性和骨髓抑制，心脏毒性发生率Ａ、Ｂ两组均为５％（１例），骨髓抑制Ａ组较Ｂ组稍高，白细胞下降率各为６５．０％和５５．０％．结论：高剂量表阿霉素为主的联合化疗治疗ＮＳＣＬＣ的有效率比常规剂量组高，毒性相似，可以耐受，是值得推荐的高效低毒的一种给药途径．
Objective: To compare the curative rate and the side effects of the high-dose epirubicin with mitomycin and cisplatin (group A) with regular-dose epirubicin with mitomycin and cisplatin (group B) in the treatment of untreated non-small cell lung cancer. Methods A total of 40 cases with untreated NSCLC entered this trial. They were randomly and averagely divided into group A and group B (most of them were diagnosed as adenocarcinoma, among which 4 were in Ⅲa-stage, 17 in Ⅲb stage and 19 in Ⅳ stage) and received chemotherapy of high-dose epirubicin with mitomycin and cisplatin or regular-dose epirubicin with mitomycin and cisplatin respectively. Results: Overall curative rate in Group A was 65%, which was more significant than Group B (45%). The mean survival time was 8.7 months in Group A and 7.1 months in Group B. The dose related side effects of epirubicin were heart toxicity and leucopneia. 2 cases appeared heat toxicity and the incidence of leucopneia in group A (65%) was higher than that in Group B (50%). Conclusions: This study demonstrated that high-dose epirubicin with mitomycin and cisplatin had a better effect than regular dose for NSCLC. The toxicity was tolerable.
出处
《伤残医学杂志》
2000年第2期16-19,共4页
Medical Journal of Trauma and Disability
